STOCK TITAN

Allogene Therapeutics Inc - ALLO STOCK NEWS

Welcome to our dedicated news page for Allogene Therapeutics (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Allogene Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Allogene Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.22%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.15%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
conferences earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.82%
Tags
none
Allogene Therapeutics Inc

Nasdaq:ALLO

ALLO Rankings

ALLO Stock Data

754.15M
110.18M
22.44%
73.78%
14.86%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
South San Francisco

About ALLO

allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le